Key components of increased drug expenditure in South Korea: implications for the future

Hye-Young Kwon, Bongmin Yang, Brian Godman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: The cost of pharmaceuticals has increased rapidly in Korea in recent years. Expenditure is likely to grow further with the policy of expanding NHI coverage for four disease areas including cerebrovascular and cardiovascular disease, rare diseases and cancer. Consequently, there is a need to analyse the different components leading to this increased expenditure as a basis for suggesting future reforms in Korea.
Objective: Quantify the impact of new and established drugs on the growth of total drug spending in South Korea in recent years, specially focusing on the differentiated components of drug spending. These include treatment expansion and drug mix effects (switching from cheaper drugs to expensive ones and vice versa).
Materials and Method: A model was proposed and used to assess the impact of both new and existing drugs on changes in price, quantity, and drug mix over the 5-year period in Korea from 2006 to 2010. The database used was the National Health Insurance claims data, which covers about 97% of total population of Korea.
Results: Overall drug spending increased1.43 fold from 2006 to 2010. Drug-mix effect ( =1.32) was the main contributing factor to increased drug spending, followed by increased drug utilization ( =1.26). For existing drugs, treatment expansion ( ) and drug mix effect ( ) were measured at 1.28 and 1.24, respectively, while those of new drugs were 1.02( ) and 1.03( ). Therefore, existing drugs have a much greater effect on drug spending than new drugs. According to the Anatomical Therapeutic Classifications, drug spending rose most significantly for the “sensory organs” class of drugs ( =1.78) followed by the “various” class ( =1.68). For existing drugs in the sensory organs class (S), drug mix effect ( ) was measured at 0.96. This implies that expensive drugs among existing drugs were replaced by cheaper ones. However, the quantity prescribed ( ) substantially increased by 1.88 fold. New drugs within this class that were more expensive than existing ones were also prescribed ( =1.09) further increasing drug expenditure in Korea.
Conclusion: We found contrasting results from previous studies. The drug mix effect and existing drugs made the largest contribution to drug spending growth rather than new drugs. Policies targeting drug mix, such as promoting cost-effective prescription and rational use of drugs, including the use of cheaper cost generics without compromising care, should be primarily considered to help contain future drug expenditure.
LanguageEnglish
Pages14-21
Number of pages8
JournalValue in Health Regional Issues
Volume6
Early online date29 Mar 2015
DOIs
Publication statusPublished - 1 May 2015

Fingerprint

Republic of Korea
Health Expenditures
Pharmaceutical Preparations
Korea
South Korea
Expenditure
Drugs
Costs and Cost Analysis

Keywords

  • pharmaceutical expenditure
  • new drugs
  • drug mix
  • established drugs
  • Korea
  • medical treatments
  • health economics

Cite this

@article{587a67c56dc646218605ed3a1bcf1282,
title = "Key components of increased drug expenditure in South Korea: implications for the future",
abstract = "Introduction: The cost of pharmaceuticals has increased rapidly in Korea in recent years. Expenditure is likely to grow further with the policy of expanding NHI coverage for four disease areas including cerebrovascular and cardiovascular disease, rare diseases and cancer. Consequently, there is a need to analyse the different components leading to this increased expenditure as a basis for suggesting future reforms in Korea.Objective: Quantify the impact of new and established drugs on the growth of total drug spending in South Korea in recent years, specially focusing on the differentiated components of drug spending. These include treatment expansion and drug mix effects (switching from cheaper drugs to expensive ones and vice versa). Materials and Method: A model was proposed and used to assess the impact of both new and existing drugs on changes in price, quantity, and drug mix over the 5-year period in Korea from 2006 to 2010. The database used was the National Health Insurance claims data, which covers about 97{\%} of total population of Korea. Results: Overall drug spending increased1.43 fold from 2006 to 2010. Drug-mix effect ( =1.32) was the main contributing factor to increased drug spending, followed by increased drug utilization ( =1.26). For existing drugs, treatment expansion ( ) and drug mix effect ( ) were measured at 1.28 and 1.24, respectively, while those of new drugs were 1.02( ) and 1.03( ). Therefore, existing drugs have a much greater effect on drug spending than new drugs. According to the Anatomical Therapeutic Classifications, drug spending rose most significantly for the “sensory organs” class of drugs ( =1.78) followed by the “various” class ( =1.68). For existing drugs in the sensory organs class (S), drug mix effect ( ) was measured at 0.96. This implies that expensive drugs among existing drugs were replaced by cheaper ones. However, the quantity prescribed ( ) substantially increased by 1.88 fold. New drugs within this class that were more expensive than existing ones were also prescribed ( =1.09) further increasing drug expenditure in Korea. Conclusion: We found contrasting results from previous studies. The drug mix effect and existing drugs made the largest contribution to drug spending growth rather than new drugs. Policies targeting drug mix, such as promoting cost-effective prescription and rational use of drugs, including the use of cheaper cost generics without compromising care, should be primarily considered to help contain future drug expenditure.",
keywords = "pharmaceutical expenditure, new drugs, drug mix, established drugs, Korea, medical treatments, health economics",
author = "Hye-Young Kwon and Bongmin Yang and Brian Godman",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.vhri.2015.01.004",
language = "English",
volume = "6",
pages = "14--21",
journal = "Value in Health Regional Issues",
issn = "2212-1099",

}

Key components of increased drug expenditure in South Korea : implications for the future. / Kwon, Hye-Young; Yang, Bongmin; Godman, Brian.

In: Value in Health Regional Issues, Vol. 6, 01.05.2015, p. 14-21.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Key components of increased drug expenditure in South Korea

T2 - Value in Health Regional Issues

AU - Kwon, Hye-Young

AU - Yang, Bongmin

AU - Godman, Brian

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction: The cost of pharmaceuticals has increased rapidly in Korea in recent years. Expenditure is likely to grow further with the policy of expanding NHI coverage for four disease areas including cerebrovascular and cardiovascular disease, rare diseases and cancer. Consequently, there is a need to analyse the different components leading to this increased expenditure as a basis for suggesting future reforms in Korea.Objective: Quantify the impact of new and established drugs on the growth of total drug spending in South Korea in recent years, specially focusing on the differentiated components of drug spending. These include treatment expansion and drug mix effects (switching from cheaper drugs to expensive ones and vice versa). Materials and Method: A model was proposed and used to assess the impact of both new and existing drugs on changes in price, quantity, and drug mix over the 5-year period in Korea from 2006 to 2010. The database used was the National Health Insurance claims data, which covers about 97% of total population of Korea. Results: Overall drug spending increased1.43 fold from 2006 to 2010. Drug-mix effect ( =1.32) was the main contributing factor to increased drug spending, followed by increased drug utilization ( =1.26). For existing drugs, treatment expansion ( ) and drug mix effect ( ) were measured at 1.28 and 1.24, respectively, while those of new drugs were 1.02( ) and 1.03( ). Therefore, existing drugs have a much greater effect on drug spending than new drugs. According to the Anatomical Therapeutic Classifications, drug spending rose most significantly for the “sensory organs” class of drugs ( =1.78) followed by the “various” class ( =1.68). For existing drugs in the sensory organs class (S), drug mix effect ( ) was measured at 0.96. This implies that expensive drugs among existing drugs were replaced by cheaper ones. However, the quantity prescribed ( ) substantially increased by 1.88 fold. New drugs within this class that were more expensive than existing ones were also prescribed ( =1.09) further increasing drug expenditure in Korea. Conclusion: We found contrasting results from previous studies. The drug mix effect and existing drugs made the largest contribution to drug spending growth rather than new drugs. Policies targeting drug mix, such as promoting cost-effective prescription and rational use of drugs, including the use of cheaper cost generics without compromising care, should be primarily considered to help contain future drug expenditure.

AB - Introduction: The cost of pharmaceuticals has increased rapidly in Korea in recent years. Expenditure is likely to grow further with the policy of expanding NHI coverage for four disease areas including cerebrovascular and cardiovascular disease, rare diseases and cancer. Consequently, there is a need to analyse the different components leading to this increased expenditure as a basis for suggesting future reforms in Korea.Objective: Quantify the impact of new and established drugs on the growth of total drug spending in South Korea in recent years, specially focusing on the differentiated components of drug spending. These include treatment expansion and drug mix effects (switching from cheaper drugs to expensive ones and vice versa). Materials and Method: A model was proposed and used to assess the impact of both new and existing drugs on changes in price, quantity, and drug mix over the 5-year period in Korea from 2006 to 2010. The database used was the National Health Insurance claims data, which covers about 97% of total population of Korea. Results: Overall drug spending increased1.43 fold from 2006 to 2010. Drug-mix effect ( =1.32) was the main contributing factor to increased drug spending, followed by increased drug utilization ( =1.26). For existing drugs, treatment expansion ( ) and drug mix effect ( ) were measured at 1.28 and 1.24, respectively, while those of new drugs were 1.02( ) and 1.03( ). Therefore, existing drugs have a much greater effect on drug spending than new drugs. According to the Anatomical Therapeutic Classifications, drug spending rose most significantly for the “sensory organs” class of drugs ( =1.78) followed by the “various” class ( =1.68). For existing drugs in the sensory organs class (S), drug mix effect ( ) was measured at 0.96. This implies that expensive drugs among existing drugs were replaced by cheaper ones. However, the quantity prescribed ( ) substantially increased by 1.88 fold. New drugs within this class that were more expensive than existing ones were also prescribed ( =1.09) further increasing drug expenditure in Korea. Conclusion: We found contrasting results from previous studies. The drug mix effect and existing drugs made the largest contribution to drug spending growth rather than new drugs. Policies targeting drug mix, such as promoting cost-effective prescription and rational use of drugs, including the use of cheaper cost generics without compromising care, should be primarily considered to help contain future drug expenditure.

KW - pharmaceutical expenditure

KW - new drugs

KW - drug mix

KW - established drugs

KW - Korea

KW - medical treatments

KW - health economics

UR - http://www.journals.elsevier.com/value-in-health-regional-issues/

U2 - 10.1016/j.vhri.2015.01.004

DO - 10.1016/j.vhri.2015.01.004

M3 - Article

VL - 6

SP - 14

EP - 21

JO - Value in Health Regional Issues

JF - Value in Health Regional Issues

SN - 2212-1099

ER -